Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
- Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after standard of care treatments or are ineligible or intolerant to standard of care for recurrent or stage IVB cervical cancer (Arms A, B and C only).
- Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D and E only).
- Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on or after at least one but no more than two prior systemic therapies for recurrent or stage IVB cervical cancer (Arm F and G only).
- Must have baseline measurable disease per RECIST v1.1.
- Must be at least 18 years of age on the day of signing informed consent (All Arms).
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (All Arms).
- Is not pregnant, breastfeeding, or expecting to conceive children within the projected duration of the trial and for at least 6 months after the last trial treatment administration
- Women of childbearing potential must agree to use adequate contraception during and for 6 months after the last dose of trial treatment administration.
- Must sign an informed consent form (ICF) indicating the trial subject understands the purpose of and procedures required for the trial and are willing to participate in the trial (All Arms).
- Has clinically relevant bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage. (All Arms)
- Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal surgery are permitted. (All Arms)
- Has clinically significant bleeding issues or risks
- Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or more) (Arm A only)
- Recent (within 4 weeks of first dose of trial treatment) clinically significant gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arm A only)
- Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing complications that require medical intervention (Arm A only)
- Has active ocular surface disease at baseline. Subjects with prior history of cicatricial conjunctivitis are ineligible (All Arms).
- Clinically significant cardiac disease
- Requires anti-coagulation therapy
Salt Lake City
The dose escalation part will occur in cervical cancer subjects who have progressed during or
after standard of care therapy and who are intolerant or ineligible to receive standard of
care treatments. Arm A will be conducted by escalating doses of both tisotumab vedotin and
bevacizumab. Dose escalations of the tisotumab vedotin + pembrolizumab and tisotumab vedotin
+ carboplatin combinations (Arms B and C, respectively) will be conducted by combining fixed
doses of either pembrolizumab or carboplatin with increasing doses of tisotumab vedotin.
The dose expansion part will consist of subjects with recurrent or stage IVB cervical cancer,
who have not received prior systemic therapy for their recurrent or stage IVB disease, Arms D
and E being treated with tisotumab vedotin + carboplatin or tisotumab vedotin +
pembrolizumab, respectively, or subjects, who have progressed on or after standard of care
treatments, Arm F treated with tisotumab vedotin + pembrolizumab and Arm G treated with
tisotumab vedotin alone. Subjects enrolled to Arms D, E, and F will receive the RP2D of
tisotumab vedotin established in the dose escalation part. Subjects enrolled to Arm G will
receive tisotumab vedotin weekly for three weeks and 1 week off (28 day treatment cycle).
Trial Phase Phase I/II
Trial Type Treatment
- Primary ID GCT1015-05
- Secondary IDs NCI-2019-01361, InnovaTV 205, MK3475 KN 834
- Clinicaltrials.gov ID NCT03786081